 this is a follow - up to the question we asked on the last call. 
 we want to know what you think about the prospects for the atopic derm market with the launch of atogepant and atopic dermatitis with the launch of atogepant in the second half of the year and the launch of atopic dermatitis with the launch of atopic dermatitis in the second half of the year with the launch of atogepant. 
 we want to know what your expectations are for the launch of atogepant and for the launch of atopic dermatitis and for the launch of atogepant in psoriasis and for the launch of atopic dermatitis in psoriasis in the second half of the year.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in    # 1#2#3#4#1 * # 2 *, # 3 ( # 4 ) # 1#2#3#4#5#6#7#8 * # 1 *, # 2 ( # 3 ) # 1#2#3#9#10 * # 1 *, # 2 ( # 9 ) # 10 * # 1 *, # 2 ( # 10 ) # 11 * # 12 *, # 13 *, # 14 *, # 15 *, # 16 *, # 17 *, # 18 *, # 19 *, # 20 *, # 21 *, # 22 *, # 23 *, # 24 *, # 25 *, # 26 *, # 27 *, # 28 *, # 29 *, # 30 *, # 31 *, # 40 *, # 41 *, # 50 *, # 51 *, # 60 *, # 61 *, # 62 *, # 63 *, # 70 *, # 80 *, # 81 *, # 82 *, # 87 *, # 91 *, # 92 *, # 93 *, # 94 *, # 110 *, # 111 *, # 112 *, # 113 *, # 114 *, # 115 *, # 126 *, # 136 *, # 135 *, # 136 *, # 139 *, # 145 *, # 156 *, # 153 *, # 156 *, # 156 *, # 157 *, # 158 *, # 158 *, # 159 *, # 161 *, # 161 *, # 162 *, # 217 *, # 217 *, # 18 *, # 217 *, # 22 *, # 217 *, # 23 *, # 217 *, # 217 * ], # 22 *, # 217 *,